An observational study in Aortic Stenosis, Transcatheter Aortic Valve Implantation and Bicuspid Aortic Valve, sponsored by National University of Ireland, Galway, Ireland. Enrolling by invitation at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-21.
Sponsored by National University of Ireland, Galway, Ireland · Observational
The goal of the NEO2 BAV registry is to investigate the safety, effectiveness, and clinical performance of TAVI using the ACURATE neo2 valve in patients with severe BAV stenosis.
The clinical, procedural, and imaging characteristics will be collected from patients with severe BAV stenosis, regardless of the phenotype, and treated with TAVI using the ACURATE neo2 bioprosthesis worldwide.
As the use of TAVI in BAV anatomy expands, it is important to systematically evaluate clinical outcomes from various THV technologies among BAV patients. It is essential to consider short-, and longer-term events among patients with BAV undergoing TAVI. Short-term outcomes of interest include THV embolization, PVL, residual transvalvular gradients and patient prosthesis mismatch, aortic root rupture, the requirement for new PPI, and stroke. Longer-term term clinical events of interest include quality of life, THV durability, freedom from reintervention, maintained coronary access, the possibility of redo-TAVI, and mortality.
The ACURATE neo2 THV has design features that make it possible to successfully treat severe BAV stenosis and yield optimal short- and longer-term outcomes. A new active sealing skirt is designed to minimize residual PVL; this is especially relevant given the presence of severe calcifications in BAV. The supra-annular leaflet position is also likely to provide excellent haemodynamics and durability since they sit above the heavily calcified native valve leaflet calcification. The upper crown and stabilizing arches and the top-down deployment of the ACURATE neo2 should reduce the risk of device embolization. It is unclear however if the self-expanding frame of the neo2 has the optimal radial force to treat patients with severe calcification.
The plan is to collect systematic clinical, procedural, and imaging data on a large series of patients with severe symptomatic BAV stenosis who underwent TAVI using the ACURATE neo2 THV. This information will show if the ACURATE neo2 is suitable to treat BAV morphology and determine if there are specific BAV subtypes that are more suitable for alternative treatment strategies. It is also envisaged that this study will inform the procedural execution of ACURATE neo2 THV in BAV morphology and inform future iteration design of the ACURATE neo THV series.
All imaging data (Echocardiography, angiography, aortography and MSCT) will be meticulously analyzed in an independent imaging Core Lab (CORRIB Core Lab, University of Galway, Galway, Ireland).
The in-depth imaging analysis will allow the identification of patients that are suitable for TAVI using the ACURATE neo2 system and highlight patient or procedural features that render TAVI at elevated risk of adverse outcomes. Furthermore, a mechanistic understanding of the device-host interaction will be examined on post-TAVI multislice computed tomography (MSCT) and other available post-TAVI imaging studies.
1,025 studies on the registry are indexed under Aortic Valve Stenosis; 293 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 435 observational studies indexed under Aortic Valve Stenosis.
Browse Aortic Valve Stenosis studies →National University of Ireland, Galway, Ireland is the lead sponsor of 47 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with severe BAV stenosis and treated with TAVI using ACURATE neo2 THV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with severe symptomatic BAV stenosis who underwent TAVI using the ACURATE neo2 THV.
Device: Transcatheter Aortic Valve Implantation
TAVI in patients with severe BAV stenosis using ACURATE neo2
Also known as: ACURATE neo2 Aortic valve system
VARC-3 device success
1. Number of patients with technical success. 2. Number of patients with death from any cause. 3. Number of patients with surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication. 4. Number of patients with intended performance of the valve (mean gradient \<20 mmHg, peak velocity \<3 m/s, Doppler velocity index ≥0.25, and less than moderate AR), defined as the presence of all of the following:
Time frame: 30-Day
VARC-3 early safety
1. Number of patients with death from any cause. 2. Number of patients with stroke. 3. Number of patients with VARC type 2-4 bleeding. 4. Number of patients with major vascular, access-related, or cardiac structural complication. 5. Number of patients with acute kidney injury stage 3 or 4. 6. Number of patients with moderate or severe aortic regurgitation 7. Number of patients with new pacemaker due to procedure related conduction abnormalities 8. Number of patients with surgery or intervention related to the device
Time frame: 30-Day
VARC-3 clinical efficacy (at 1 year and thereafter)
1. Number of patients with death from any cause. 2. Number of patients with stroke. 3. Number of patients with hospitalization (procedure or Valve related causes).
Time frame: 1-year
Valve-related long-term clinical efficacy (at 5 years and thereafter)
1. Number of patients with bioprosthetic Valve Failure (defined as: Valve related mortality OR Aortic valve re-operation/re-intervention or Stage 3 hemodynamic valve deterioration) 2. Number of patients with stroke. 3. Number of patients with VARC Type 2-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents, used specifically for valve-related concerns.
Time frame: 5-year
Plan to share: Undecided — not decided yet
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Mar 2024, 5 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University of Ireland, Galway, Ireland